CarePlusOne’s Diverse Healthcare Product Portfolio
By integrating diverse healthcare solutions under one roof, the company strengthens its role as a comprehensive partner in health and wellness.
CarePlusOne’s product lineup spans a wide range of medical and healthcare categories, catering to both professional institutions and general consumers. The company distributes raw pharmaceutical ingredients, prescription drugs, over-the-counter (OTC) products, medical devices, and functional healthcare goods.In its OTC segment, CarePlusOne offers items such as hydrocolloid bandages and pain relief patches designed for first-aid and everyday wellness. These products combine practical utility with user-friendly design, making them essential in homes, clinics, and professional environments.
On the prescription side, the company works with a variety of therapeutic categories, including antibiotics, anesthetics, dermatological agents, and hormonal treatments, supported by longstanding relationships with domestic pharmaceutical manufacturers.
Additionally, CarePlusOne supplies selected medical devices and wound care products that align with the company’s emphasis on safety, reliability, and ethical sourcing. By integrating diverse healthcare solutions under one roof, the company strengthens its role as a comprehensive partner in health and wellness.
Company Name : careplusone
Name : KIM DO HYUNG
Phone : +82 10-5531-3707
Email : [email protected]
Websit : http://www.careplusone.co.kr
Address : Suite 201, Commercial Building,
Sejong Grancia Apartment,
12 Suyeong-ro (Munhyeon-dong), Nam-gu,
Busan, Republic of Korea
- Contact Email
- [email protected]
- Issued By
- careplusone
- Country
- Korea, Republic of
- Categories
- Advertising · Business · Consumer
- Last Updated
- February 25, 2026
Disclaimer: This press release was submitted by a registered PRFree contributor and has not been verified or endorsed by PRFree. PRFree assumes no responsibility or liability for its accuracy, content, legality, or reliability. The contact email for this release can be viewed here. See our Disclaimer.